Global Auto-Injectors Market 2023
Description
The global auto-injectors market exhibits strong growth potential, forecast to grow at a CAGR of 13.4% from 2022-2029 to reach a value of USD 101.8 billion by 2029. Rising prevalence of chronic conditions like rheumatoid arthritis, multiple sclerosis and anaphylaxis which require regular self-administration of medication. This drives demand for convenient auto-injector devices among patients.
Technological advancements enabling minimally invasive drug delivery, shorter needle lengths for improved comfort, and add-on monitoring tools to track dosage. Companies are innovating to enhance performance and user experience. Favorable trends like the shift towards home healthcare due to COVID-19 pandemic restrictions, and the growing geriatric population susceptible to chronic illnesses. This is increasing adoption of self-injectable devices.
However, the preference among some patient populations for alternative delivery methods like pre-filled syringes, pens, and pumps may restrain uptake. Complex regulatory requirements also pose hurdles in new product approvals.
Market Segmentation
The market is segmented based on product type, route of administration, therapy, end user, and geography.
Segmentation by Product Type
Disposable Autoinjectors
Reusable Autoinjectors
Segmentation by Route of Administration
Intramuscular
Subcutaneous
Segmentation by Therapy
Anaphylaxis
Diabetes
Multiple Sclerosis
Rheumatoid Arthritis
Others (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia)
Segmentation by End User
Ambulatory Care
Home Care Settings
Hospital and Clinics
Segmentation by Geography
North America %li%United States, Canada, Mexico
Europe %li%United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific %li%China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America %li%Brazil, Argentina, and Rest of Latin America
Middle East and Africa %li%GCC, South Africa, and Rest of Middle East and Africa
Rheumatoid arthritis (RA) represents a key therapy area driving growth within the global auto-injectors market. RA is an autoimmune condition causing chronic joint inflammation and pain due to the immune system mistakenly attacking healthy tissue. It has higher prevalence among the elderly female population.
As populations age, the incidence of RA is expected to increase, along with demand for self-injectable treatments that are convenient and simple to administer. Studies demonstrate RA patients using auto-injectors have better outcomes and find the devices more comfortable versus conventional injections by caregivers.
Companies are also promoting improved user experience through design advancements like hidden needles and ergonomic shapes. Such initiatives around patient centricity and innovation are catalyzing uptake of auto-injectors for RA treatment.
Geographically, North America accounts for a major share of the disposable auto-injectors market. Early adoption of new products, a steady pace of regulatory approvals and rising chronic disease prevalence make the region conducive for market growth. Specifically, the United States represents a lucrative market, aided by rapid uptake of technological advancements, new product introductions and expanding patient populations requiring self-administered drug delivery.
Competitive Landscape
The Auto-Injectors market is highly competitive and includes major players like Abbvie Inc., Amgen Inc., Antares Pharma, Inc. (Halozyme Therapeutics, Inc.), Becton Dickinson and Co., Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Ypsomed AG, among others, who hold a significant market share.
Recent Industry Developments
In May 2022, Jabil Healthcare, a division of Jabil Inc., launched the Qfinity autoinjector platform, providing a cost-effective solution for subcutaneous drug self-administration.
Also in May 2022, Stevanato Group S.p.A. formed an exclusive agreement with Owen Mumford Ltd. for its Aidaptus auto-injector.
Scope of the Report
To analyze and forecast the market size of the global auto-injectors market.
To classify and forecast the global auto-injectors market based on product type, route of administration, therapy, end user, geography.
To identify drivers and challenges for the global auto-injectors market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global auto-injectors market.
To identify and analyze the profile of leading players operating in the global auto-injectors market.
Why Choose This Report
Gain a reliable outlook of the global auto-injectors market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
The global auto-injectors market exhibits strong growth potential, forecast to grow at a CAGR of 13.4% from 2022-2029 to reach a value of USD 101.8 billion by 2029. Rising prevalence of chronic conditions like rheumatoid arthritis, multiple sclerosis and anaphylaxis which require regular self-administration of medication. This drives demand for convenient auto-injector devices among patients.
Technological advancements enabling minimally invasive drug delivery, shorter needle lengths for improved comfort, and add-on monitoring tools to track dosage. Companies are innovating to enhance performance and user experience. Favorable trends like the shift towards home healthcare due to COVID-19 pandemic restrictions, and the growing geriatric population susceptible to chronic illnesses. This is increasing adoption of self-injectable devices.
However, the preference among some patient populations for alternative delivery methods like pre-filled syringes, pens, and pumps may restrain uptake. Complex regulatory requirements also pose hurdles in new product approvals.
Market Segmentation
The market is segmented based on product type, route of administration, therapy, end user, and geography.
Segmentation by Product Type
Disposable Autoinjectors
Reusable Autoinjectors
Segmentation by Route of Administration
Intramuscular
Subcutaneous
Segmentation by Therapy
Anaphylaxis
Diabetes
Multiple Sclerosis
Rheumatoid Arthritis
Others (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia)
Segmentation by End User
Ambulatory Care
Home Care Settings
Hospital and Clinics
Segmentation by Geography
North America %li%United States, Canada, Mexico
Europe %li%United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific %li%China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America %li%Brazil, Argentina, and Rest of Latin America
Middle East and Africa %li%GCC, South Africa, and Rest of Middle East and Africa
Rheumatoid arthritis (RA) represents a key therapy area driving growth within the global auto-injectors market. RA is an autoimmune condition causing chronic joint inflammation and pain due to the immune system mistakenly attacking healthy tissue. It has higher prevalence among the elderly female population.
As populations age, the incidence of RA is expected to increase, along with demand for self-injectable treatments that are convenient and simple to administer. Studies demonstrate RA patients using auto-injectors have better outcomes and find the devices more comfortable versus conventional injections by caregivers.
Companies are also promoting improved user experience through design advancements like hidden needles and ergonomic shapes. Such initiatives around patient centricity and innovation are catalyzing uptake of auto-injectors for RA treatment.
Geographically, North America accounts for a major share of the disposable auto-injectors market. Early adoption of new products, a steady pace of regulatory approvals and rising chronic disease prevalence make the region conducive for market growth. Specifically, the United States represents a lucrative market, aided by rapid uptake of technological advancements, new product introductions and expanding patient populations requiring self-administered drug delivery.
Competitive Landscape
The Auto-Injectors market is highly competitive and includes major players like Abbvie Inc., Amgen Inc., Antares Pharma, Inc. (Halozyme Therapeutics, Inc.), Becton Dickinson and Co., Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Ypsomed AG, among others, who hold a significant market share.
Recent Industry Developments
In May 2022, Jabil Healthcare, a division of Jabil Inc., launched the Qfinity autoinjector platform, providing a cost-effective solution for subcutaneous drug self-administration.
Also in May 2022, Stevanato Group S.p.A. formed an exclusive agreement with Owen Mumford Ltd. for its Aidaptus auto-injector.
Scope of the Report
To analyze and forecast the market size of the global auto-injectors market.
To classify and forecast the global auto-injectors market based on product type, route of administration, therapy, end user, geography.
To identify drivers and challenges for the global auto-injectors market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global auto-injectors market.
To identify and analyze the profile of leading players operating in the global auto-injectors market.
Why Choose This Report
Gain a reliable outlook of the global auto-injectors market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
PART 1. INTRODUCTION
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL AUTO-INJECTORS MARKET BY PRODUCT TYPE
5.1 Disposable autoinjectors
5.2 Reusable autoinjectors
PART 6. GLOBAL AUTO-INJECTORS MARKET BY ROUTE OF ADMINISTRATION
6.1 Intramuscular
6.2 Subcutaneous
PART 7. GLOBAL AUTO-INJECTORS MARKET BY THERAPY
7.1 Anaphylaxis
7.2 Diabetes
7.3 Multiple sclerosis
7.4 Rheumatoid arthritis
7.5 Others
PART 8. GLOBAL AUTO-INJECTORS MARKET BY END USER
8.1 Ambulatory care
8.2 Home care settings
8.3 Hospitals and clinics
PART 9. GLOBAL AUTO-INJECTORS MARKET BY GEOGRAPHY
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Latin America
9.5 Middle East & Africa
PART 10. COMPANY PROFILES
10.1 Abbvie Inc.
10.2 Amgen Inc.
10.3 Antares Pharma, Inc. (Halozyme Therapeutics, Inc.)
10.4 Becton Dickinson and Co.
10.5 Eli Lilly and Company
10.6 GSK plc
10.7 Johnson & Johnson
10.8 Merck KGaA
10.9 Novartis AG
10.10 SHL Medical AG
10.11 Teva Pharmaceutical Industries Ltd.
10.12 Ypsomed AG
DISCLAIMER
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL AUTO-INJECTORS MARKET BY PRODUCT TYPE
5.1 Disposable autoinjectors
5.2 Reusable autoinjectors
PART 6. GLOBAL AUTO-INJECTORS MARKET BY ROUTE OF ADMINISTRATION
6.1 Intramuscular
6.2 Subcutaneous
PART 7. GLOBAL AUTO-INJECTORS MARKET BY THERAPY
7.1 Anaphylaxis
7.2 Diabetes
7.3 Multiple sclerosis
7.4 Rheumatoid arthritis
7.5 Others
PART 8. GLOBAL AUTO-INJECTORS MARKET BY END USER
8.1 Ambulatory care
8.2 Home care settings
8.3 Hospitals and clinics
PART 9. GLOBAL AUTO-INJECTORS MARKET BY GEOGRAPHY
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Latin America
9.5 Middle East & Africa
PART 10. COMPANY PROFILES
10.1 Abbvie Inc.
10.2 Amgen Inc.
10.3 Antares Pharma, Inc. (Halozyme Therapeutics, Inc.)
10.4 Becton Dickinson and Co.
10.5 Eli Lilly and Company
10.6 GSK plc
10.7 Johnson & Johnson
10.8 Merck KGaA
10.9 Novartis AG
10.10 SHL Medical AG
10.11 Teva Pharmaceutical Industries Ltd.
10.12 Ypsomed AG
DISCLAIMER
